ISRCTN94385648已完成未知
ow molecular weight heparin (LMWH) (dalteparin) versus unfractionated heparin (UFH) for deep vein thrombosis (DVT) prevention: a randomised, concealed, stratified, placebo-controlled, blinded, parallel assignment trial
Hamilton Health Sciences (Canada)0 个研究点目标入组 3,650 人开始时间: 2008年5月21日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3,650
研究概览
简要总结
- 2011 results in: https://www.ncbi.nlm.nih.gov/pubmed/21417952 (added 10/04/2019) 2. 2011 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/21482348 (added 10/04/2019) 3. 2013 results in: https://www.ncbi.nlm.nih.gov/pubmed/23788287 (added 10/04/2019) 4. 2013 results in: https://www.ncbi.nlm.nih.gov/pubmed/23942857 (added 10/04/2019) 5. 2014 results in: https://www.ncbi.nlm.nih.gov/pubmed/24726205 (added 10/04/2019) 6. 2014 economic evaluation in: https://www.ncbi.nlm.nih.gov/pubmed/25528663 (added 10/04/2019) 7. 2015 results in: https://www.ncbi.nlm.nih.gov/pubmed/26356708 (added 10/04/2019) 8. 2016 results in: https://www.ncbi.nlm.nih.gov/pubmed/26921148 (added 10/04/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Admission to Intensive Care Unit (ICU)
- •2. Men or women greater than or equal to 18 years of age
- •3. Actual body weight greater than or equal to 45 kg
- •4. Admission to ICU expected to be greater than or equal to 72 hours in duration
排除标准
- •1. Trauma, post-orthopedic surgery or post-neurosurgery patients
- •2. Uncontrolled hypertension (systolic greater than 180 mmHg or diastolic greater than 110 mmHg)
- •3. Major haemorrhage, haemorrhagic stroke, DVT or PE on admission or within last three months
- •4. Coagulopathy as defined by international normalised ratio (INR) greater than two times upper limit of normal [ULN], or partial thromboplastin time (PTT) greater than two times ULN
- •5. Thrombocytopenia defined as platelet count less than or equal to 75 x 10^9/L
- •6. Need for oral or intravenous or subcutaneous therapeutic anticoagulation
- •7. Receipt of greater than three days of UFH or LMWH in ICU
- •8. Contraindication to heparin (e.g., suspected HIT), blood products or pork products
- •9. Pregnant or lactating
- •10. Withdrawal of life support or limitation of life support
- •11. Current enrolment in this trial or a related trial
- •12. Lack of informed consent
研究者
相似试验
进行中（未招募）
1 期
ow molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in patients with stage IIIb and IV NSCLC undergoing a cisplatin based first line chemotherapy: the syringes trial - SYRINGESEUCTR2007-007696-16-BETOGA Thoracic Oncology Group Antwerp
已完成
3 期
A study to know the effect of low molecular weight heparin in treatment of acute pancreatitis.CTRI/2021/04/032665SMS Medical Jaipur140
进行中（未招募）
1 期
Heparin in the treatment of fetal growth restrictioEUCTR2020-000315-76-PTCentro Hospitalar Universitário de Lisboa Central, EPE120
已完成
不适用
Pharmacokinetics of Dalteparin in Patients With Impaired Renal FunctionRenal InsufficiencyNCT00264693Luzerner Kantonsspital96
已完成
不适用
Pharmacokinetics of Low Molecular Weight Heparin in Cancer PatientsCancerThrombosisAngina PectorisNCT00716898Shaare Zedek Medical Center25